HLS Therapeutics Inc. (HLTRF) Stock

About HLS Therapeutics Inc.

HLS Therapeutics Inc. is a specialized pharmaceutical firm engaged in the acquisition and commercialization of medicinal products, with a primary focus on the central nervous system (CNS) and cardiovascular (CV) therapeutic areas. The company's activities extend across Canada, the United States, and international territories. Its core product lineup features Clozaril, an atypical antipsychotic medication prescribed for schizophrenia; Vascepa, composed of icosapent ethyl capsules; and PERSERIS, an injectable risperidone formulation also employed in the treatment of schizophrenia. Beyond pharmaceuticals, HLS Therapeutics offers MyCare psychiatry laboratory assays and MyCare Insite point-of-care diagnostic tests for monitoring drug levels. Additionally, the company possesses U.S. marketing rights for Absorica, a commercially available dermatology product, along with Canadian rights for Trinomia, a cardiovascular therapeutic. It also benefits from royalty streams derived from four other healthcare products. HLS Therapeutics Inc. was founded in 2018 and maintains its headquarters in Etobicoke, Canada.

HLS Therapeutics Inc. is headquartered in CA.

HLS Therapeutics Inc. (HLTRF) stock trades at $2.98 with a market capitalization of $93.20M. The stock is valued at a price-to-earnings (P/E) ratio of -9.24, price-to-book of 1.59, price-to-sales of 1.67. Over the past 52 weeks the stock has ranged between $2.98 and $4.02, and currently trades 25.9% below its 52-week high.

On profitability, HLS Therapeutics Inc. generates a return on equity (ROE) of -16.54%, return on capital employed of -3.99%, an operating margin of -7.34%, a net profit margin of -18.42%.

Official website: www.hlstherapeutics.com